Dr. Kumar is Professor, Medical Oncology at Tata Memorial Hospital and has more than two decades of experience. He has published over a hundred research and review articles/papers in journals of national and international repute.He has undertaken over 80 projects as Principal Ivestigator and Co-Investigator.He is a member of many international and national scientific societies and associations and has delivered talks in several conferences.
Internship at Maulana Azad Medical College - New Delhi from Jan 1995 to Feb 1996.
Post Graduate Residency in General Medicine at Maulana Azad Medical College, New Delhi - May 1996 to Oct 1999
Senior Residency at Maulana Azad Medical College Hospital, New Delhi - Feb 2000 to Sep 2000.
Super Specialty training in Medical Oncology - October 2000 to October 2003.
Clinical Assistant –RGCI, New Delhi-Dec 2003-Nov 2004
Asst Prof ,Medical Oncology, TMH, Mumbai-Dec 2004 till 2006
Assoc Prof, TMH, Mumbai. 2007 to 2011
Prof, TMH, Mumbai. 2011 till date
Supervisor- Medical Oncology Molecular Laboratory from 2008 till date
Research Fellow at Fred Hutchinson Cancer Research Center, Seattle
Skin toxicity management of EGFR TKI - Published
Recurrent and metastatic head and neck cancer management-Published
Advanced renal cell cancer management - Published
Advanced lung cancer management – In press
Esophageal cancer management by ICMR – Submitted
5 most important publications –
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2017 Apr 27;2(1)(Corresponding Author)
Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents.Asia Pac J Clin Oncol. 2017 Aug 28. (Corresponding Author)
Drug-sensitive FGFR3 mutations in lung adenocarcinoma. Ann Oncol. 2017 Mar 1;28(3):597-603. (First Author) (400 pts adeno Ca molecular profiling done)
A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol. 2015 Mar;51(3):279-86. (Corresponding Author
Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India. Support Care Cancer. 2016 Apr;24(4):1595-602. (Corresponding Author)